On June 26, 2007, the House Ways and Means Health Subcommittee held a public hearing on safety concerns regarding the dosing of erythropoiesis stimulating agents (ESAs), variations in utilization of ESAs across providers, and reimbursement issues. Oral testimony at this hearing was from invited witness es only. However, individuals and/or organizations not scheduled for an oral appearance were invited to submit a written statement for consideration by the Committee and for inclusion in the printed record of the hearing. The Kidney Care Partners, of which ANNA is a member, submitted written testimony. Click here to read the full text of the written testimony (Word, 56.5KB).